Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) EBT (2019 - 2025)

Historic EBT for Harmony Biosciences Holdings (HRMY) over the last 7 years, with Q3 2025 value amounting to $67.5 million.

  • Harmony Biosciences Holdings' EBT rose 855.72% to $67.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $230.5 million, marking a year-over-year increase of 3143.7%. This contributed to the annual value of $191.8 million for FY2024, which is 1061.62% up from last year.
  • According to the latest figures from Q3 2025, Harmony Biosciences Holdings' EBT is $67.5 million, which was up 855.72% from $49.6 million recorded in Q2 2025.
  • In the past 5 years, Harmony Biosciences Holdings' EBT registered a high of $67.5 million during Q3 2025, and its lowest value of -$10.5 million during Q3 2021.
  • In the last 5 years, Harmony Biosciences Holdings' EBT had a median value of $39.7 million in 2023 and averaged $35.9 million.
  • Examining YoY changes over the last 5 years, Harmony Biosciences Holdings' EBT showed a top increase of 5968888.89% in 2021 and a maximum decrease of 65117.86% in 2021.
  • Harmony Biosciences Holdings' EBT (Quarter) stood at $24.5 million in 2021, then surged by 80.2% to $44.1 million in 2022, then dropped by 10.01% to $39.7 million in 2023, then soared by 41.49% to $56.2 million in 2024, then grew by 20.19% to $67.5 million in 2025.
  • Its last three reported values are $67.5 million in Q3 2025, $49.6 million for Q2 2025, and $57.2 million during Q1 2025.